Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882258 · ClinicalTrials.gov registry record · Phase 2
Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
A Phase 2 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
NCT00882258: Completed Phase 2 study, sponsored by Repros Therapeutics.
NCT00882258 is a Phase 2 study that has completed, run by Repros Therapeutics. The registered enrollment target is 144 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00882258, a Phase 2 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
Study Summary
Two (2) dose levels of Proellex or placebo will be administered once-daily for up to 91 days. Following screening and a pre-treatment endometrial biopsy, subjects will be followed monthly for the three month treatment phase.
Interventions
- DRUG Placebo
- DRUG 25 mg Proellex
- DRUG 12.5 mg Proellex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
What the finished NCT00882258 record still lists
NCT00882258 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00882258 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00882258 about?
NCT00882258 is a clinical study titled "Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids". Two (2) dose levels of Proellex or placebo will be administered once-daily for up to 91 days. Following screening and a pre-treatment endometrial biopsy, subjects will be followed monthly for the three month treatment phase.
What is the current status of trial NCT00882258?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2006-03. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00882258?
The interventions under investigation include: Placebo (DRUG), 25 mg Proellex (DRUG), 12.5 mg Proellex (DRUG).
Who is sponsoring clinical trial NCT00882258?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00882258's enrollment target sits among peer trials
144 500th of 2000 higher than 1,494 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia